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A B S T R A C T
Purpose: This retrospective audit was to assess the effect of the New General Practitioner (GP) Contract
and National Institute for Health and Care Excellence (NICE) guidelines on the care and management of
people with epilepsy (PWE) during the period of observation from April 2004 to April 2009.
Method: The case notes of 540 people on anti-epilepsy drugs (AEDs) aged 16 years were reviewed in 13
general practices serving Ellesmere Port and Neston.
Results: Forty-nine percent of people with poorly controlled epilepsy were not under shared care.
Diagnostic doubt existed in 25 (5%) people. There was no evidence that the original diagnosis had been
actively reviewed by the GP in any case. There were 98 (18%) women of childbearing age, in 21 of whom
there was no evidence of pre-conceptual counselling ever having taken place, and 61 (62%) were not
receiving folic acid routinely. Thirty-nine (7%) people were demonstrably non-compliant, whilst 74
(14%) people had prescription anomalies consisting mainly of inappropriate multi-dose regimens.
Conclusion: Despite marked improvements in review rates after the introduction of the New GP Contract
ﬁve years previously, there are still signiﬁcant unmet needs in this patient group. Clinical Commissioning
Groups (CCGs) should consider funding an intermediate tier of care incorporating GPs with a special
interest in epilepsy (GPwSIes) and Epilepsy Nurse Specialists (ENS) for PWE to improve and maintain
existing and future primary care, as epilepsy is phased out of the Quality and Outcomes Framework
(QOF).
 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
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The New General Practitioner (GP – family physician) Contract,
which was introduced in April 2004, listed epilepsy as one of the
core quality indicators of the Quality and Outcomes Framework
(QOF, a system for the performance management and payment of
GPs in the National Health Service (NHS) in England, Scotland,
Wales and Northern Ireland replacing various other fee arrange-
ments).1 GPs were required to establish a register of all people with
epilepsy (PWE) on treatment, record their seizure frequency,
‘review’ their medication, and hence calculate the percentage
having been ‘convulsion free’ in the previous twelve months
(Table 1).
Since the introduction of the New Contract it has been
consistently demonstrated that there have been signiﬁcant* Corresponding author. Tel.: +44 1244564319; fax: +44 1244370762.
E-mail address: ian.minshall@nhs.net (I. Minshall).
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1059-1311/ 2014 British Epilepsy Association. Published by Elsevier Ltd. All rights reimprovements in annual review rates and seizure documentation
in primary care.2–4 In April 2014 epilepsy was removed from the
QOF.
In October 2004 the National Institute for Health and Clinical
Excellence (NICE, a non-departmental public body of the United
Kingdom Department of Health that publishes, amongst others,
guidelines and clinical appraisals based on evaluations of efﬁcacy
and cost effectiveness on the treatment and management of
speciﬁc conditions and diseases) published comprehensive guide-
lines, which were subsequently modiﬁed in 2012,5 for the care of
adult PWE. The following recommendations are relevant to this
study:
 The primary seizure type(s) and epilepsy syndrome, aetiology
and co-existing co-morbidities should be determined. The AED
treatment regimen should be individualised according to the
seizure type, epilepsy syndrome, co-medication and co-morbid-
ities, the individual’s lifestyle, and the preferences of the
individual, their family and/or carers as appropriate.served.
Table 1




Epilepsy 1. The practice can produce a




Epilepsy 2. The percentage of patients
age 16 and over on drug treatment
for epilepsy who have a record of seizure
frequency in the previous 15 months
4 90%
Epilepsy 3. The percentage of patients
age 16 and over on drug treatment for
epilepsy who have a record of medication
review in the previous 15 months
4 90%
Epilepsy 4. The percentage of patients
age 16 and over on drug treatment
for epilepsy who have been convulsion
-free for last 12 months recorded
in last 15 months
6 70%
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uncertainty or treatment failure, individuals should be referred
to tertiary services soon for further assessment.
 Annual GP review should include an enquiry about side effects
and a discussion of the treatment plan to ensure optimal AED
compliance. Bone health, for those PWE on enzyme inducing
drugs, should be monitored.
 The decision whether to continue or withdraw AEDs in people
in long term remission should be taken following a discussion
with the individual, their family and/or carers as appropriate,
and the specialist about the risks and beneﬁts of AED
withdrawal. At the end of the discussion, individuals and their
family and/or carers as appropriate, should understand the
individual’s risk of seizure recurrence on and off treatment. This
discussion should take into account details of the individual’s
epilepsy syndrome, prognosis and lifestyle. Withdrawal of
AEDs must be managed by, or under the guidance of, the
specialist.
 Women with epilepsy and their partners, as appropriate, must be
given accurate information and counselling about contraception,
conception, pregnancy, caring for children, breastfeeding and
menopause. All women on AEDs should be offered 5 mg of folic
acid daily before any possibility of pregnancy.
NICE guidelines recommend sodium valproate as the AED of
choice for idiopathic generalised epilepsy, except in women of
child bearing age, whilst lamotrigine and carbamazepine are
considered the AEDs of choice for partial onset seizures.6,7
NICE also recommends people being prescribed vigabatrin
should have annual ophthalmological review due to the risk of
visual ﬁeld defects.8
Whilst it is well recognised that since the introduction of the
New Contract the majority of PWE are now at least reviewed
annually by their GP, it remains to be seen if this translates into
meaningful clinical beneﬁt for people with epilepsy or if it simply
constitutes another tick box exercise.
2. Methods
The practice case notes of 540 people aged 16 years and over
with a diagnosis of epilepsy in receipt of repeat prescriptions for
AEDs were reviewed, focusing on GP consultations from April 2004
to April 2009. The study was carried out, in 13 practices serving
Ellesmere Port and Neston, from June 2009 to January 2010 byDr Minshall (IM), a GP with Special Interest in epilepsy (GPwSIe)
since 2005.
The following audit criteria were recorded:
1. A review of the original diagnosis based on the correspondence
from secondary care and investigation results (neuro-imaging
and EEG) where available, and the identiﬁcation of cases where
there was potential diagnostic doubt. In those people with poor
control was their AED prescription appropriate for their epilepsy
classiﬁcation.
2. Review of AED prescriptions: dosing regimens and compliance
based on prescription collection (failure to collect three or more
monthly prescriptions per year).
3. For people in remission for longer than 10 years, assessment of
documentation whether a discussion concerning AED with-
drawal had taken place.
4. Identifying people under shared care and in particular the
proportion with poorly controlled epilepsy (documented
seizures within the last year) not under secondary care.
5. Documentation of pre-conceptual counselling taking place in
women of childbearing age (18–50 yrs, not on HRT, or with a
documented hysterectomy or infertility or sterilisation) and
proportion taking folic acid 5 mg.
6. Identiﬁcation of those people being prescribed an AED
associated with a detrimental effect on bone health for over
10 years.
2.1. Statistics
Categorical variables were analysed using x2 test, using SPSS
13.0 (SPSS Inc., Chicago, IL, USA). A p value of <0.05 was considered
to be statistically signiﬁcant.
3. Results
There were 540 people (male 266:274 female). Data from the
local PCT ﬁgures revealed annual review rates of 96% in 2007–08
and 93% in 2008–09.4
3.1. Review of diagnosis
From examination of the notes there were 26 (5%) people
identiﬁed by one of the authors (IM) in whom he felt there was
signiﬁcant diagnostic doubt about the original documented
diagnosis of epilepsy (in the majority of cases there was clear
documented evidence of an alternative diagnosis, either in the
hospital correspondence (for example non-epileptic attack disor-
der), a diagnosis based on investigations (abnormal EEG), or a
documented description of a patient’s typical episode strongly
suggested the possibility of an alternative diagnosis (such as
syncope)) yet a persistent diagnosis of epilepsy was retained by the
GP, and a further 15 (3%) people where the epileptic syndrome was
inaccurate with inappropriate AED prescription (Table 2). There
was no documented evidence that the original diagnoses of
epilepsy or the epileptic syndrome had been actively reviewed by
the GP in any person.
3.2. Anti-epileptic drug prescriptions
There were 74 (13%) people with anomalies relating to their
prescriptions, mainly inappropriate dosing regimens, once daily
prescriptions of twice daily drugs, and low dosages below
usual therapeutic levels. There was one person prescribed
vigabatrin, who was not under annual ophthalmological review
(Table 3).
Table 2
People with diagnostic doubt and possibly misclassiﬁed.
Diagnostic doubt 26 (5%)
Non-epileptic attack disorder (NEAD)
(of which based on EEG)
15 (4)
Syncope (of which based on EEG) 5 (2)
Based on an EEG result rather than clinical grounds 4
Temper outbursts 1
Un-witnessed blackouts 1
Under shared care 1
No events >10 years 10
Uncontrolled idiopathic epilepsy never on valproate
(non-under shared care, 2 male, 1 female >50 yrs)
3
Uncontrolled partial epilepsy on
valproate (non-under shared care)
12
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of repeat prescriptions), of whom three were on inappropriate
regimes (three or four times daily, p = ns) and nine (23%) had had
no documented seizures for over 10 years.
3.3. Seizure remission
One hundred and eighteen PWE (22%) had been seizure free for
longer than 10 years, of whom only seven had evidence of a
discussion concerning the option of AED withdrawal.
3.4. Poorly controlled epilepsy
There were 150 (28%) people with documented poorly
controlled epilepsy, 73 (49%) of whom were not under shared care.
3.5. Epilepsy and women
There were 98 women of child bearing age (16–50), 21 (21%) of
whom had no documented evidence of pre-conceptual counselling
and only 37 (38%) were receiving a regular prescription of folic
acid.
3.6. Bone health
Three hundred and eighty-two (71%) were prescribed an AED
known to effect bone health for 10 years or longer, none of whom
were receiving Vitamin D supplementation.
4. Discussion
For clinicians with an interest in epilepsy who were aware of
the unmet needs associated with the condition, its inclusion was a
welcome addition to the QOF targets when the New GP Contract
was introduced in 2004. Unfortunately, for the GP, fewer ﬁnancial
points were allocated to the condition compared with other
chronic diseases such as ischaemic heart disease or diabetes
mellitus. The principal requirements of the epilepsy QOF targets
were to establish a register, document seizure frequency having at
least 70% of people ‘convulsion’ free and ‘review medication’ wereTable 3
Prescribing anomalies identiﬁed.
Once daily prescription of divided dose drug
(where patient not controlled)
14 (4%)
Low dose prescription (where patient not controlled) 5 (1%)
Drug combinations with very similar pharmacological
properties where person not controlled
1
Patient on vigabatrin not under ophthalmological care 1
Tds prescriptions 42 (7.8%)
Qds prescriptions 11 (2%)clinically limited, driven more by quantitative measurement
rather than a comprehensive quality review. There was no
incentive, admittedly signiﬁcantly more challenging, for GPs to
review the original diagnosis and management.
With annual QOF review rates for PWE now exceeding 90%
compared to pre-QOF rates of 19%,2 an objective evaluation of the
clinical impact of such increased annual rates is required hence the
need for a study such as this.
One of the main issues with the annual GP review mandated by
QOF is what GPs can be reasonably be expected to do and what is
beyond their remit. We accept that epilepsy can be complex and
therefore that the optimal management of refractory epilepsy is
beyond the experience and knowledge of most GPs. It is however
generally accepted that the model of care for people with difﬁcult
to treat epilepsy is one of a joint care model between primary and
secondary/tertiary care. Similarly people with long-term seizure
control, on or off AEDs are typically solely managed in primary care.
Consequently we believe that to have genuine shared care, there
must be areas of management over which GPs could realistically
take responsibility for and which ideally should have been reﬂected
in the QOF targets. In particular recording of seizure frequency
(with referral to neurology services of all PWE with sub-optimal
control), review of dosing regimens (not AED regimens), side-
effects, AED compliance, monitoring of bone health in appropriate
PWE, assessing mental health, and basic advice regarding
conception and contraception in women should reasonably fall
within the remit of GPs. More complex issues should be managed at
a secondary/tertiary level or alternatively by a GPwSIe/Epilepsy
Nurse Specialist (ENS) combination in a primary care setting.
Encouraging referral for those people with poorly controlled
epilepsy is important in order to review the diagnosis itself, and
once established, classify and prescribe AEDs appropriately.9,10 The
proportion of people in this study with documented poorly
controlled epilepsy (deﬁned as documented seizures in the past
year) not under shared care was 49%. This equates to similar rates
found in adjacent geographical areas; 45% in Chester in 20053 and
49% the rural practices in 2008.11 The consistency of these ﬁgures,
suggests QOF has not had an impact on referral rates to secondary
care.
Discussion of AED withdrawal in people in long-term remission
requires knowledge of their correct epileptic syndrome in addition
to knowledge of the literature. Whilst withdrawal of AEDs should
be performed under specialist supervision, consequently necessi-
tating referral (if not under dual care),12 the initial discussion about
AED withdrawal should take place in primary care. The impact on
driving is the usual reason why people are reluctant to consider
AED withdrawal,13 however it is still worth documenting that such
a discussion has taken place.
Compliance with medication is important for PWE to
maintain control. Regimes over twice daily dosing have been
linked to poor compliance.14 However in this study only three
(9%) people not collecting prescriptions regularly were on multi-
dose regimes and therefore is unlikely to have been a signiﬁcant
in non-compliance.
The issues and counselling required around AED prescribing for
women of childbearing age also need up to date information which
might be best facilitated by referral to/with advice from an ENS.
The addition since 2011 of questions relating to contraception and
pre-conception in the QOF requirements were welcome.
Epilepsy is associated with a high incidence of mental health
problems especially anxiety and depression (not assessed in this
paper).15 The GP has the skill to assess this and can therefore
identify and manage affective disorders or refer onwards when
appropriate.
The effect of AEDs on bone metabolism must be considered.
Clear guidelines are required to help GPs manage this important
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exposed to an AED associated with bone loss for 10 years or
more.16
This study highlights the continuing deﬁcits in the quality of
care of PWE, despite the introduction of QOF and NICE guidelines.
We would argue that QOF, with hindsight, needed to be more
holistic and could perhaps have been better worded as follows:
‘Create an epilepsy register. Discuss poor control and long term
remission, review the medication regimen, focussing on
compliance, side effects, issues for women of childbearing
age, mental health, and bone metabolism. Refer appropriately’.
– 16 points
This would have been a framework and reminder for GPs on
which to base their care with an emphasis on referral to specialist
services or dual care where appropriate.
From April 2014 epilepsy will no longer be included in QOF,
therefore the ﬁnancial incentive to review PWE will vanish.
Hopefully GPs will see the beneﬁts of a yearly clinical review and
continue to do so, and maintain recall registers. Similarly it is
hoped that PWE themselves, will continue to advocate for annual
GP review. Inevitably removal of epilepsy from QOF will result in a
signiﬁcant reduction in GP reviews although whether or not this
will negatively impact on patient care remains to be seen.
This study has highlighted the potential impact on the care, of
this group of PWE, that a review by one of the authors, a GPwSIe
could have achieved.
One of the potential limitations of this study is that it was based
on a retrospective note review which is dependent on the
completeness of the notes, as lack of documentation does not
necessarily equate to lack of action.
Now is the time for CCGs (CCGs are commissioning groups in
geographical areas which were set up by the Health and Social Act
2012 to organise services in NHS England. The aim of the CCGs is to
give GPs and other clinicians the power to inﬂuence commission-
ing decisions for their patients.) to consider the future provision of
care for PWE in the community and with that comes the potential
to review alternative treatment paradigms in primary care. In
particular we would contend that GPwSIes in association with
Epilepsy Nurse Specialists could successfully be able to fulﬁl the
role of an intermediary between primary and secondary care for
the management of PWE. Further data is however required to
verify the clinical impact and efﬁcacy of an enhanced primary care
service (GPwSIe) on the management of PWE in the community.
In our opinion QOF failed to deliver its optimum potential of
improving primary care management of PWE. Despite this, it is
clear that QOF has resulted in signiﬁcant improvement in annual
review rates whilst highlighting unmet needs in care. Thosedeﬁciencies need to be addressed medically and ﬁnancially more
effectively. This will require investment by CCGs now, before we
miss another opportunity.
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